Oral delivery remains the preferred route for small molecule drugs, offering patient convenience, simplified manufacturing, and lower development costs. Yet despite its advantages, oral bioavailability remains a critical barrier in early-stage development. Many promising drug candidates fail to reach clinical proof of concept, not because of a lack of efficacy, but because of insufficient absorption.
This eBook explores how you can tackle poor oral bioavailability with a structured early formulation strategy. It outlines the tools available to predict and address solubility-limited exposure, and how platforms like Upperton’s UpperSolv™ can help you make faster, more informed decisions using minimal API and delivering results for highly sensitive timelines.
Oral delivery remains the preferred route for small molecule drugs, offering patient convenience, simplified manufacturing, and lower development costs. Yet despite its advantages, oral bioavailability remains a critical barrier in early-stage development. Many promising drug candidates fail to reach clinical proof of concept, not because of a lack of efficacy, but because of insufficient absorption.
Whitepaper Contents:
- The Bioavailability Bottleneck
- Developability Classification System
- Causes of Poor Bioavailability
- UpperSolv: Identifying Formulation Strategy to Maximise Success in the Clinic
- UpperSolv Case Studies